American Society of Hirudotherapy

Chronic Pelvic Pain Syndrome (Non-Specific)

Investigational for non-specific chronic pelvic pain; the only clinical report located is an uncontrolled 60-woman series in which leeches were one part of multimodal care.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for chronic pelvic pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and only within a multimodal management framework.
What evidence exists?
Tier C (investigational). There are no controlled trials; the only clinical report located is an uncontrolled series of 60 women treated with leeches as one part of a multimodal programme (Iskhakova 2021). Non-specific chronic pelvic pain (no identified structural cause) affects an estimated 6 to 15 percent of reproductive-age women. Standard care is multimodal: pelvic-floor physical therapy, cognitive behavioral therapy, trigger-point management, and pharmacotherapy (gabapentinoids, tricyclics, hormonal modulation). Single-modality use of any therapy is not recommended.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the lower abdomen, sacrum, or inner thigh for 5 to 10 days
  • Local skin infection or Aeromonas infection
  • Allergic reaction to leech saliva
  • Triggering of additional pelvic-floor spasm if bite is near a trigger area
  • Failure to address an underlying structural pathology if workup is incomplete
  • Delay of evidence-based pelvic-floor physical therapy, CBT, or pharmacotherapy
  • Substitution for multimodal therapy with single-modality leech sessions
Who should not consider this
  • Patients with untreated structural pathology (endometriosis, fibroids, ovarian cyst, adhesions) — workup first
  • Patients with active pelvic infection (PID, abscess)
  • Pregnant or lactating patients
  • Patients with bleeding disorders or on anticoagulants
  • Patients with anemia
  • Patients who have not engaged with pelvic-floor physical therapy and behavioral therapy
What to ask your clinician
  • Has my workup excluded structural causes (endometriosis, fibroids, adhesions, ovarian pathology)?
  • Am I receiving pelvic-floor physical therapy from a certified pelvic-floor PT?
  • Have I been considered for cognitive behavioral therapy and pain psychology?
  • Have neuropathic agents (gabapentin, duloxetine, tricyclics) been considered?
  • Where exactly will the leech be placed, and what is the multimodal integration plan?
  • What is the realistic expected benefit, given that the only clinical report located is one uncontrolled series in which leeches were one part of multimodal care?
When to seek urgent care
  • Sudden severe pelvic or abdominal pain (rule out acute pathology)
  • Heavy or unusual vaginal bleeding
  • Fever above 38.0 C / 100.4 F, chills, or pelvic tenderness
  • Signs of infection (urinary, vaginal, gastrointestinal)
  • Bleeding from a bite site lasting more than 24 hours
  • Spreading redness, warmth, pus, or red streaks at any bite site

What this does NOT mean

  • It does not substitute for pelvic-floor physical therapy, cognitive behavioral therapy, or pharmacotherapy, which together have the strongest evidence.
  • It does not work for structural pelvic pathology like endometriosis or fibroids, which need specific evidence-based treatment.
  • It is not recommended as single-modality therapy — integration with the multimodal plan is essential.
  • Only one uncontrolled multimodal series (60 women) was located, so benefit beyond multimodal therapy alone is uncertain.

Clinical Profile

Category
Gynecologic
ICD-10
R10.2, N94.89
Safety tier
Medium

Evidence Summary

Non-specific chronic pelvic pain (no identified structural cause) affects an estimated 6-15% of reproductive-age women. No controlled clinical trial of leech therapy for non-specific chronic pelvic pain was identified in PubMed, Europe PMC, Crossref or ClinicalTrials.gov. The only clinical report located is an uncontrolled series of 60 women aged 16-42 with chronic pelvic pain treated with manual therapy, hirudotherapy, reflexotherapy and psychotherapy together; clinical and neurophysiological indicators improved, but the effect of leeches alone cannot be separated (Iskhakova et al. 2021, Vestnik Novykh Meditsinskikh Tekhnologii). Older Russian reports, summarized in Baskova and Isakhanyan 2004, concern chronic adnexitis, an inflammatory pelvic condition. Any use is investigational. A proposed mechanism involves modulation of central sensitization and local pelvic-floor decongestion, but this is unproven. Any exploratory use should be integrated with evidence-based care — pelvic-floor physical therapy, cognitive behavioral therapy, and trigger-point management — rather than used as a single modality.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan do not describe chronic pelvic pain as a separate condition; they write about inflammatory diseases of the female genital organs — parametritis, adnexitis, salpingo-oophoritis — and in one of the observations note that after treatment the feeling of heaviness, pain and tension in the lower abdomen lessened[B1].
  • In the section for gynecologists they write that, according to several authors, leeches have a favorable therapeutic effect on the course of inflammatory diseases of the female genital organs[B1].
  • They retell the observation by Galchenko and Shkolny (1969) of 25 patients with chronic adnexitis: hirudotherapy was part of a complex of anti-inflammatory treatment, and afterwards, according to their report, general condition, sleep, appetite and mood improved, the feeling of heaviness, pain and tension in the lower abdomen lessened, and the uterine appendages became more mobile and less tender; no comparison group is named in this description[B1].
  • They also give a comparison: Khardikov, Gazazyan and Ivanova (2003) observed 20 women with chronic salpingo-oophoritis who received leeches together with the usual anti-inflammatory treatment, and 30 women who received only the usual treatment; according to their report, signs of inflammation subsided more often in the women who received leeches, and some women in the control group showed no positive change; how the women were assigned to the groups is not stated in the retelling[B1].
  • Baskova and Isakhanyan write that the use of leeches is contraindicated in inflammation of the pelvic peritoneum (pelvioperitonitis) and of the lining of the uterus (endometritis), because of the possible spread of blood poisoning (sepsis) and development of a clotting disorder (DIC syndrome)[B1].
  • Among the general contraindications they name hemophilia, hemorrhagic diatheses, anemias and concurrent use of anticoagulants, and they recommend refraining from hirudotherapy when body temperature is high[B1].
  • Michalsen et al. (the chapter on contraindications by Flecken and Michalsen) write that hirudotherapy during the acute stage of infectious diseases may, in their experience, lead to weakness and impaired wound healing[B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Untreated structural pathology (rule out before treatment)
  • Active pelvic infection

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.